SUMMARY
OBJECTIVE:
In endometrial cancer surgery, sentinel lymph node dissection is used instead of staging surgery, particularly in advanced disease that is limited to the uterus. The aim of this study is to evaluate our practice of robotic sentinel lymph node dissection, which is applied to endometrial cancer patients in our tertiary cancer treatment center, according to the current literature, and to share our own data.
METHODS:
Included in our analysis are patients who underwent robotic sentinel lymph node dissection for endometrial cancer utilizing indocyanine green in our center between January 2018 and January 2024.
RESULTS:
In all, of the 93 endometrial carcinoma patients who underwent sentinel lymph node biopsy, 63 were classified as low-risk, while 30 were high-risk according to the European Society of Gynaecological Oncology and National Comprehensive Cancer Network guidelines. We found sentinel lymph nodes in both low-risk and high-risk patients, with an overall sensitivity of 96.32% (95% confidence interval [CI], 85.12–99.71), specificity of 100% (95%CI, 92.20–99.8), negative predictive value of 96.72% (95%CI, 87.03–99.89), and negative likelihood ratio of 0.06 (95%CI, 0.01–0.36).
CONCLUSION:
After evaluating our data retrospectively, we determined that we were compatible with the current literature.
KEYWORDS:
Sentinel lymph node; Endometrium cancer; Robot assisted surgery